Cipla
1,515.70
+9.80(+0.65%)
Market Cap₹1,21,632.70 Cr
PE Ratio23.63
IndustryHealthcare
Company Performance:
1D+0.65%
1M+3.09%
6M-0.88%
1Y+2.47%
5Y+141.70%
View Company Insightsright
Latest news about Cipla
Cipla's Bengaluru Facility Receives One Observation in USFDA CGMP Inspection Jun 02, 2025
Cipla's Bengaluru Facility Receives Single FDA Observation After Inspection May 30, 2025
CIPLA's Bengaluru Facility Receives One FDA Observation After Inspection May 30, 2025
Cipla Expands European Presence with New German Subsidiary May 29, 2025
More news about Cipla
21May 25
Cipla's Abraxane Drug Launch Faces Stiff Competition from Chinese Firms
Cipla is facing unexpected challenges in launching its Abraxane drug due to competition from Chinese firms that have already secured FDA approvals and ANDAs. UBS reports this could reduce Cipla's earnings per share by 5.00%. The company's strategy to navigate this competitive landscape will be crucial for its market position and financial performance.
20May 25
CIPLA Invests in Green Energy: Acquires 26% Stake in AMPIN Energy for Solar Power Project
CIPLA has acquired a 26% stake in AMPIN Energy C&I Eighteen to develop a captive solar power project in Maharashtra. This investment aims to integrate renewable energy into CIPLA's operations, potentially reducing long-term energy costs, enhancing sustainability efforts, and improving energy security. The move aligns with the broader trend in the Indian pharmaceutical sector towards adopting green energy solutions.
14May 25
Cipla's Q4 Results Meet Expectations, FY26 EBITDA Margin Guidance Viewed as Conservative
Cipla reported strong Q4 results, meeting revenue and EBITDA estimates. The company's India business grew 8% YoY, while US revenue reached $221 million. For FY26, Cipla projects an EBITDA margin of 23.5-24.5%, which analysts view as conservative. The company exceeded its current year guidance by 150 basis points. Cipla is now focusing on EBITDA margin guidance rather than revenue targets, emphasizing profitability. Despite challenges like loss of exclusivity for generic Revlimid, Cipla expects continued growth. Analysts maintain a positive outlook with 'Buy' and 'Outperform' ratings.
13May 25
Cipla's Q4 Results: Revenue Beats Estimates, Profit Surges 30%; Warns of Future Margin Decline
Cipla's Q4 FY2023 results exceeded expectations with revenue up 9% to ₹6,729.69 crore and net profit rising 30% to ₹1,222.00 crore. EBITDA grew 17% to ₹1,538.00 crore, with margins improving to 22.80%. Despite strong performance, Cipla forecasts EBITDA margin declines to 23.5-24.5% in FY26 and a further 300 basis point drop in FY27, primarily due to the phasing out of gRevlimid. The company expects flat US business revenue in Q1 of the new fiscal year but projects continued topline growth.
12May 25
Cipla Ltd. Sets Date for Q4 and FY25 Results, Dividend Announcement
Cipla Ltd. has scheduled a board meeting for May 13, 2025, to review and approve Q4 and FY2025 financial results and consider a final dividend recommendation. The company has implemented a trading window closure from April 1 to May 15, 2025, to ensure fair trading practices. An earnings call is set for May 13, 2025, at 4:00 PM to discuss the results with investors and analysts.
09May 25
Cipla Ltd. Anticipates Mixed Q4 FY25 Results Amid Market Challenges
Cipla Ltd. is set to release Q4 FY25 results on May 13. Analysts project a 9.70% increase in net profit to Rs 1,023.10 crore. US operations face challenges due to Lanreotide supply issues and a weak respiratory season. India business expected to grow 9-10% year-over-year, boosted by Sanofi agreement. South African operations show strong performance due to Actor Pharma acquisition and tender sales recovery. FY25 EBITDA margins expected to align with 25.50% guidance, but concerns exist for FY26 margins.
21Mar 25
Cipla's Stock Set to Benefit from FTSE All World Index Weight Upgrade
Cipla, a leading Indian pharmaceutical company, has received a weight upgrade in the FTSE All World Index. This upgrade is projected to attract approximately $30.40 million (₹2.60 billion) in foreign investment inflows. The increased weighting is expected to enhance Cipla's visibility among global investors, potentially lead to increased passive fund inflows, and provide support to the stock price.
18Mar 25
Cipla Expands Dermatology Portfolio with Multi-Regional Licensing Deal
Cipla Limited has entered into a multi-regional licensing agreement with Formosa Pharmaceuticals for Clobetasol Propionate Topical Solution (Suspension). The deal primarily targets the United States market, with potential expansion to other territories. This strategic move aims to strengthen Cipla's presence in the global dermatology market, particularly in the competitive US sector. The agreement grants Cipla commercialization rights for the dermatological product, which is a potent corticosteroid used to treat various skin conditions.
21Feb 25
CIPLA's Subsidiary Sitec Labs Receives USFDA Observations; Company Secures Approval for Nilotinib Capsules
USFDA conducted a CGMP inspection at CIPLA's subsidiary Sitec Labs, issuing two Form 483 observations. CIPLA plans to address these promptly. Simultaneously, CIPLA received USFDA approval for Nilotinib Capsules, an oncology drug for chronic myeloid leukemia, with launch expected in FY 2025-26.
20Feb 25
Cipla Secures FDA Approval for Nilotinib Capsules, Eyes 2025-26 US Launch
Cipla Limited has received final USFDA approval for its New Drug Application for Nilotinib capsules in 50 mg, 150 mg, and 200 mg strengths. The drug is used to treat Philadelphia chromosome-positive chronic myeloid leukemia. Cipla plans to launch the product in the US market during fiscal year 2025-26, strengthening its position in the oncology segment.
Cipla
1,515.70
+9.80
(+0.65%)
1 Year Returns:+2.47%
Industry Peers
Sun Pharmaceutical
1,667.20
(-0.51%)
Divis Laboratories
6,856.50
(+0.69%)
Cipla
1,515.70
(+0.65%)
Torrent Pharmaceuticals
3,416.70
(+0.25%)
Dr Reddys Laboratories
1,276.80
(-0.51%)
Zydus Life Science
1,002.50
(+1.27%)
Mankind Pharma
2,287.00
(-1.41%)
Lupin
1,960.90
(+1.18%)
Abbott
34,665.00
(-2.82%)
Aurobindo Pharma
1,132.50
(-0.20%)